These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31551514)

  • 1. Cyclooxygenase-2 is critical for the propagation of β-amyloid protein and reducing the glycosylation of tau in Alzheimer's disease.
    Guan PP; Yu X; Zou YH; Wang P
    Cell Mol Immunol; 2019 Nov; 16(11):892-894. PubMed ID: 31551514
    [No Abstract]   [Full Text] [Related]  

  • 2. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new kind of Alzheimer's disease plaque.
    Baum L; Ng HK
    Adv Anat Pathol; 1998 May; 5(3):170-4. PubMed ID: 9868523
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for Alzheimer disease.
    Gouras GK
    MAbs; 2009; 1(2):112-4. PubMed ID: 20061820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.
    Rajamohamedsait H; Rasool S; Rajamohamedsait W; Lin Y; Sigurdsson EM
    Sci Rep; 2017 Dec; 7(1):17034. PubMed ID: 29213096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse models of Alzheimer's disease: the long and filamentous road.
    Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
    Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss in efficacy measures of tolfenamic acid in a tau knock-out model: Relevance to Alzheimer's disease.
    Leso A; Bihaqi SW; Masoud A; Chang JK; Lahouel A; Zawia N
    Exp Biol Med (Maywood); 2019 Oct; 244(13):1062-1069. PubMed ID: 31450960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.
    Ontiveros-Torres MÁ; Labra-Barrios ML; Díaz-Cintra S; Aguilar-Vázquez AR; Moreno-Campuzano S; Flores-Rodríguez P; Luna-Herrera C; Mena R; Perry G; Florán-Garduño B; Luna-Muñoz J; Luna-Arias JP
    J Alzheimers Dis; 2016 Mar; 52(1):243-69. PubMed ID: 27031470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of immunosignatures to the assessment of Alzheimer's disease.
    Restrepo L; Stafford P; Magee DM; Johnston SA
    Ann Neurol; 2011 Aug; 70(2):286-95. PubMed ID: 21823156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Alzheimer's disease.
    Gelinas DS; DaSilva K; Fenili D; St George-Hyslop P; McLaurin J
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14657-62. PubMed ID: 15297619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
    Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
    Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L
    Science; 2007 May; 316(5825):750-4. PubMed ID: 17478722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice.
    Kapadia M; Mian MF; Michalski B; Azam AB; Ma D; Salwierz P; Christopher A; Rosa E; Zovkic IB; Forsythe P; Fahnestock M; Sakic B
    J Alzheimers Dis; 2018; 63(3):1191-1205. PubMed ID: 29710702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.